Business Segment Information

6 Months Ended

Jan. 31, 2020

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

NOTE 11 — BUSINESS SEGMENT INFORMATION

The Company conducts business as two operating segments, Real Estate and Pharmaceuticals. The Company's reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company's President.

The Real Estate segment consists of the Company's real estate holdings, including a building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company and certain affiliates and its associated public garage, an office/data center building in Piscataway, New Jersey and a portion of an office building in Israel.

The Pharmaceuticals segment is comprised of preferred equity interests and the Warrant to purchase equity interests in Rafael Pharmaceuticals, a majority equity interest in LipoMedix and Barer. To date, the Pharmaceuticals segment has not generated any revenues.

The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and the Real Estate segment based primarily on results of operations. All investments in Rafael Pharmaceuticals and assets and expenses associated with LipoMedix and Barer are tracked separately in the Pharmaceuticals segment. All corporate costs are allocated to the Real Estate segment.

Operating results for the business segments of the Company are as follows:

(unaudited, in thousands)	Real Estate			Pharmaceuticals			Total
Three Months Ended January 31, 2020
Revenues	$	1,236		$	—		$	1,236
Loss from operations		(1,392	)		(514	)		(1,906	)
Three Months Ended January 31, 2019
Revenues	$	1,017		$	—		$	1,017
Loss from operations		(1,109	)		(297	)		(1,406	)

(unaudited, in thousands)	Real Estate			Pharmaceuticals			Total
Six Months Ended January 31, 2020
Revenues	$	2,446		$	—		$	2,446
Loss from operations		(2,668	)		(780	)		(3,448	)
Six Months Ended January 31, 2019
Revenues	$	2,152		$	—		$	2,152
Loss from operations		(1,823	)		(703	)		(2,526	)

Geographic Information

Revenues from tenants located outside of the United States were generated entirely from tenants located in Israel. Revenues from these non-United States customers as a percentage of total revenues were as follows (revenues by country are determined based on the location of the related facility):

Three Months Ended January 31, (unaudited)	2020			2019
Revenue from tenants located in Israel		6	%		2	%

Six Months Ended January 31, (unaudited)	2020		2019
Revenue from tenants located in Israel		6%		2	%

Net long-lived assets and total assets held outside of the United States, which are located in Israel, were as follows:

(unaudited, in thousands)	United States		Israel		Total
January 31, 2020
Long-lived assets, net	$	46,623	$	1,627	$	48,250
Total assets		135,699		3,537		139,236
July 31, 2019
Long-lived assets, net	$	47,096	$	1,637	$	48,733
Total assets		138,535		3,608		142,143